• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

CAR-T Spotlight

home / clinical-spotlight / car-t-spotlight
Ajeet Gajra, MD, FACP
January 25, 2021
Delays Mean Some Miss Window for CAR T-Cell Therapy, Cardinal Health Data Show
Data gathered by Cardinal Health Specialty Solutions revealed roadblocks community oncology practices encounter when trying to navigate payer approvals for CAR T-cell therapy.
Yi Fan
December 28, 2020
Moving a Step Closer to Using CAR T-Cell Therapy in Solid Tumors
A recent paper in Nature Cancer outlines a novel strategy for overcoming barriers to CAR T-cell therapy in glioblastoma by pretreating the vascular microenvironment.
December 18, 2020
Deepu Madduri, MD, Discusses CARTITUDE-1 Data for Multiple Myeloma—and Clinical Trials During COVID-19
At the recent meeting of the American Society of Hematology, results from several studies involved the use of chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma.
Karl Kilgore
December 15, 2020
Real-World Data Offer Good News for CAR T-Cell Therapy
Karl Kilgore, PhD, a senior research scientist at Avalere Health, discusses Medicare data that offer insights on the overall costs of CAR T-cell therapy relative to transplants.
Tanya Siddiqi, MD
November 24, 2020
Tanya Siddiqi, MD, Discusses the Promise of Reduced Toxicity With Liso-Cel
City of Hope's Dr. Tanya Siddiqi offers an update on a new chimeric antigen receptor (CAR) T-cell therapy awaiting approval from the FDA.
Duncan Allen
November 1, 2020
OneOncology’s Duncan Allen, MHA, Discusses Bringing CAR T-cell Therapy to the Community Setting
The vice president for Clinical Services at OneOncology describes challenges and opportunities for chimeric antigen receptor (CAR) T-cell therapy in the community practice setting.
© 2024 MJH Life Sciences
All rights reserved.